Compare NTR & ONC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NTR | ONC |
|---|---|---|
| Founded | 2017 | 2010 |
| Country | Canada | Switzerland |
| Employees | N/A | N/A |
| Industry | Agricultural Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 26.6B | 34.8B |
| IPO Year | N/A | N/A |
| Metric | NTR | ONC |
|---|---|---|
| Price | $62.64 | $319.15 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 17 | 12 |
| Target Price | $63.76 | ★ $369.50 |
| AVG Volume (30 Days) | ★ 2.6M | 279.4K |
| Earning Date | 11-05-2025 | 11-06-2025 |
| Dividend Yield | ★ 3.47% | N/A |
| EPS Growth | ★ 150.34 | N/A |
| EPS | ★ 3.70 | 0.58 |
| Revenue | ★ $25,671,000,000.00 | $4,972,687,000.00 |
| Revenue This Year | $6.44 | $895.40 |
| Revenue Next Year | $1.26 | $22.04 |
| P/E Ratio | ★ $16.98 | $514.97 |
| Revenue Growth | 0.45 | ★ 50.43 |
| 52 Week Low | $43.70 | $170.99 |
| 52 Week High | $65.08 | $385.22 |
| Indicator | NTR | ONC |
|---|---|---|
| Relative Strength Index (RSI) | 66.29 | 41.76 |
| Support Level | $58.04 | $315.50 |
| Resistance Level | $61.42 | $326.77 |
| Average True Range (ATR) | 1.28 | 11.23 |
| MACD | 0.35 | -3.05 |
| Stochastic Oscillator | 98.22 | 18.85 |
Created in 2018 as a result of the merger between PotashCorp and Agrium, Nutrien is the world's largest fertilizer producer by capacity. Nutrien produces the three main crop nutrients—nitrogen, potash, and phosphate—although its main focus is potash, where it is the global leader in installed capacity with a roughly 20% market share. The company is also the largest agricultural retailer in North America and Australia, selling fertilizers, crop chemicals, seeds, and services directly to farm customers through its brick-and-mortar stores and online platforms.
Founded in 2010 in Beijing and having listed on the Hong Kong exchange in 2018, BeOne is a commercial-stage biotechnology company with global sales. It focuses on oncology therapeutics and differentiates itself from other companies with a contract research organization-free, or CRO-free strategy. BeOne runs global clinical trials with its own team. As of 2024, its core drug is Brukinsa, a small molecule drug for various blood cancers that makes up more than 60% of BeOne's revenue.